Lipocine Inc. (LPCN)
LPCN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1.62
-2.41% on the day
Market cap
$13.4M
Nano cap
Revenue · 2025
$2.0M
-82.3% on 2024
Net income · 2025
-$9.6M
-487.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LPCN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001535955 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$9.6M |
| Operating income | -$10.4M |
| Net margin | -487.2% |
| Operating margin | -524.7% |
| Revenue growth | -82.3% |
| Cash | $5.2M |
| Total assets | $17.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-26 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-10-07 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 820 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GTBP | GT Biopharma Inc. | $6.50 | -4.41% | $13.4M |
| BFRI | Biofrontera Inc. | $0.8922 | -3.56% | $13.3M |
| CLRB | Cellectar Biosciences Inc. | $1.39 | -2.80% | $13.1M |
| CTXR | Citius Pharmaceuticals Inc. | $0.4760 | -3.41% | $13.1M |
| HIND | Vyome Holdings Inc. | $1.97 | -1.99% | $13.8M |
| ALLR | Allarity Therapeutics Inc. | $0.8699 | +1.14% | $13.8M |
| TVRD | Tvardi Therapeutics Inc. | $1.04 | -1.89% | $13.9M |
| KTTA | Pasithea Therapeutics Corp. | $0.4238 | -5.30% | $14.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier